Navigating the New Compliance Currents: A Mid-Year Executive Briefing

2026-06-24

The regulatory landscape for healthcare continues its rapid evolution, demanding constant vigilance from practice owners and executives. This week's digest unpacks critical FDA actions impacting patient safety and public health, alongside a significant CMS initiative poised to reshape pharmaceutical economics.

In healthcare compliance, the only constant is change, and the past week has delivered a potent reminder of this immutable truth. From critical FDA safety updates influencing patient counseling to a foundational CMS inquiry set to reshape the multi-billion-dollar Pharmacy Benefit Manager (PBM) industry, the currents of regulation are intensifying. For telehealth founders, brick-and-mortar practice owners expanding nationally, compliance officers, and healthcare investors, staying ahead of these shifts is not merely advisable — it is a strategic imperative. This digest provides a curated briefing on the most impactful developments, offering a TrueEval perspective on what these changes signify for your operations and future strategy.

> For more on this topic, see our analysis: [Q2 Compliance Watch: Navigating FDA Supply Chain Enforcement, OTC Drug Shifts, and PBM Transparency Demands](/blog/q2-compliance-watch-fda-otc-pbm-demands).

Heightened Scrutiny on OTC Medications: Beyond the Prescription Pad

Recent actions by the U.S. Food and Drug Administration (FDA) underscore an expanding focus on the safety and labeling of even over-the-counter (OTC) medications, demanding a more comprehensive approach to patient care across all healthcare settings. The FDA's mandated labeling updates for the OTC weight loss drug alli (Orlistat) 60 mg capsules to include warnings about rare but serious risks of acute kidney injury and kidney stones is a case in point. This update aligns the OTC product's warnings with its higher-strength prescription counterpart, Xenical, and signals a broader regulatory expectation for consumer awareness regarding potential adverse effects.

> For more on this topic, see our analysis: [The Enforcement Nexus: DOJ's Expanding Reach, FDA's Dual Focus on Access & Safety, and CMS's PBM Probe](/blog/enforcement-nexus-doj-fda-cms-pbm-probe).

The Expanding Scope of Provider Responsibility

For many healthcare providers, particularly those not directly prescribing pharmaceuticals, the notion that OTC medications could trigger compliance implications might seem distant. However, this FDA action highlights a critical, often overlooked, aspect of patient care: comprehensive medication reconciliation and patient education extend to all substances a patient consumes, prescribed or not.

Consider the implications for:

Telehealth Platforms: Many telehealth services offer weight management programs or provide general wellness advice. Patients engaging with these platforms may be self-medicating with OTC products like alli. Providers must proactively inquire about all medications, supplements, and OTC drugs during intake and follow-up, ensuring they can counsel patients on updated safety information and recognize potential symptoms of adverse reactions.
Medspas and Wellness Clinics: Practices focused on aesthetic or wellness treatments often attract patients seeking to improve their overall health, including weight management. Staff in these settings, even if not directly prescribing, should be trained to understand the risks associated with common OTC weight loss aids and to advise patients on when to consult a primary care physician or discontinue use. A simple conversation during an intake for a cosmetic procedure could become a critical intervention.
Dental and Chiropractic Practices: While seemingly outside their direct scope, patients in these settings may present with symptoms (e.g., general malaise, back pain) that could be indicative of underlying kidney issues, potentially exacerbated by OTC medications. A thorough patient history that includes all current medications, including OTCs, is essential. Furthermore, as these practices increasingly expand into broader wellness offerings, the need for comprehensive patient safety protocols grows.

This development reinforces the duty of care to remain informed about the full spectrum of products patients might be using. It necessitates robust intake processes, clear patient education materials, and ongoing staff training to ensure that potential risks, even from widely available OTC drugs, are identified and addressed proactively.

Expanding Access to Life-Saving Interventions: The OTC Naloxone Imperative

In a significant move to combat the nation's opioid crisis, the FDA has approved Rextovy, a 4 mg naloxone hydrochloride nasal spray, for over-the-counter (OTC) sale. This follows the earlier approval of Narcan for OTC use, further broadening access to this critical, life-saving medication. The federal government's continued push to make naloxone readily available without a prescription signals a shift in public health strategy, emphasizing community-level intervention and rapid response to opioid overdoses.

Beyond Prescribing: Your Role as an Educator and Community Partner

While the OTC status of Rextovy means healthcare providers are not required to prescribe it, its widespread availability profoundly impacts their role in patient care and public health. This isn't merely a pharmaceutical update; it's a societal shift in how we approach emergency opioid overdose management.

Consider the actionable implications for your practice:

Patient Education and Counseling: Providers across all specialties should be prepared to discuss the availability and proper use of OTC naloxone with patients. This is particularly crucial for:
Staff Training and Readiness: While not directly dispensing, practices should consider basic training for staff on recognizing opioid overdose symptoms and knowing where to direct patients for naloxone access. Some practices may even choose to keep naloxone on-site, a decision that should be made in consultation with legal and compliance experts.
Reducing Stigma: By openly discussing naloxone, healthcare providers can help destigmatize opioid use disorder and the use of life-saving interventions, fostering a more supportive and responsive healthcare environment.

The expansion of OTC naloxone options is a clear indicator of a public health strategy emphasizing accessibility and education. Practices that integrate this understanding into their patient care protocols not only enhance patient safety but also demonstrate a strong commitment to community health.

Unpacking the PBM Transparency Push: Future of Pharmaceutical Economics

The Centers for Medicare & Medicaid Services (CMS) has issued a Request for Information (RFI) seeking technical input on Pharmacy Benefit Managers (PBMs) and their affiliates. This RFI is a critical step in informing the implementation of recent legislation concerning PBM remuneration restrictions and data reporting requirements, set to take effect in Calendar Year 2028. While PBMs are the direct target, the ripple effects of enhanced transparency and potential structural changes will inevitably touch every corner of the healthcare ecosystem.

The Far-Reaching Implications of PBM Reform

This CMS RFI is not an isolated event; it's part of a broader, sustained governmental push to increase transparency and rein in healthcare costs, particularly those related to prescription drugs. For telehealth brands, medspas, dental practices, chiropractic offices, and other healthcare businesses, the seemingly distant world of PBMs carries significant indirect implications:

Drug Pricing and Patient Access: Greater transparency in PBM compensation and practices could lead to changes in drug pricing models. This might impact the cost of medications for patients, their out-of-pocket expenses, and ultimately, their adherence to prescribed therapies. Practices that prescribe medications will need to be attuned to how these shifts affect their patients' ability to afford and access necessary drugs.
Formulary Management and Reimbursement: PBM reforms could influence which drugs are included in formularies and the reimbursement rates for dispensing pharmacies. This, in turn, could affect prescribing patterns, the administrative burden on practices, and even the financial viability of certain treatment pathways.
Practices Engaged in Dispensing or Physician-Owned Pharmacies: For businesses that operate under Corporate Practice of Medicine (CPOM) regulations and are considering or already engaging in dispensing activities (e.g., selling certain products directly from a medspa or a chiropractic office), the evolving landscape of drug benefit management is paramount. Changes to PBM incentives could impact wholesale pricing, supply chain dynamics, and the competitive environment for dispensing entities.
Strategic Planning and Investor Relations: Healthcare investors and advisors must closely monitor these PBM reforms. The potential for shifts in drug costs, formularies, and the economics of pharmaceutical care will undoubtedly influence valuations, investment strategies, and the long-term outlook for healthcare businesses that rely heavily on pharmaceutical sales or patient adherence to drug therapies. Transparency may lead to new models for drug procurement and distribution, presenting both challenges and opportunities.
Value-Based Care and Outcomes: Ultimately, greater transparency and potentially lower drug costs could improve patient outcomes by enhancing access and affordability. Practices operating within or transitioning to value-based care models will find these PBM reforms align with their goals of delivering cost-effective, high-quality care.

The 2028 effective date may seem distant, but the groundwork for these monumental changes is being laid now. Proactive engagement and strategic foresight are crucial for navigating this evolving landscape.

What This Means For Your Practice: A Call to Proactive Compliance and Strategic Foresight

The confluence of these regulatory developments — intensified scrutiny on OTC drugs, expanded access to life-saving interventions, and a fundamental push for PBM transparency — paints a clear picture: the healthcare compliance environment is becoming more interconnected, more patient-centric, and more demanding of proactive engagement from all stakeholders.

For leaders in telehealth, medspas, dental, chiropractic, and traditional medical practices, TrueEval advises the following:

Elevate Patient Intake and Education: Implement and regularly review robust intake processes that comprehensively capture all medications, including OTCs and supplements. Develop clear, evidence-based patient education materials regarding drug risks (both prescription and OTC) and access to critical public health resources like naloxone.
Prioritize Staff Training: Ensure all clinical and administrative staff are regularly trained on updated medication safety information, patient counseling best practices, and the importance of thorough medication reconciliation. Empower them to identify potential risks and provide accurate information.
Monitor Legislative and Regulatory Trends: The CMS RFI on PBMs is a harbinger of significant future changes in pharmaceutical economics. Stay abreast of these developments, as they will directly impact your practice's operational costs, revenue streams, and patient care models. Consider how potential shifts in drug pricing and formularies could affect your strategic planning.
Review Compliance Protocols: Regularly audit your existing compliance framework to ensure it accounts for the expanding scope of patient care responsibilities, particularly concerning OTC medications and public health initiatives. This includes revisiting policies on medication reconciliation, patient counseling, and community resource referrals.

TrueEval understands that navigating this complex regulatory terrain requires more than just reacting to new mandates; it demands foresight, adaptability, and a robust compliance infrastructure. By embracing these principles, your practice can not only mitigate risk but also position itself as a leader in delivering safe, transparent, and patient-centered care in a rapidly evolving healthcare landscape.